Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

Implementation of QuickSort, MergeSort, and BucketSort algorithms for sorting manga datasets, with performance benchmarking and support for multiple sorting criteria. 💻 ...

Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027. Exscientia, now part of ...

Recursion Pharmaceuticals is harnesing the power of artificial intelligence to rapidly develop new drugs. The drugmaker's former lead candidate failed to show evidence of efficacy in a phase 2 study ...

Los Angeles—Artificial intelligence (AI)-based drug discovery continues to tout accelerated timelines and novel and effective treatments, yet today’s clinical success rates remain at a low 10%. On ...

Najat Khan, PhD, Recursion Pharmaceuticals chief R&D officer and chief commercial officer With at least seven of its programs expected to begin human trials or read out clinical data during 2025, ...

The latest chemistry news, including important research advances, business and policy trends, chemical safety practices, career guidance, and more. “Affinity was an open problem for decades,” Barzilay ...

Forbes contributors publish independent expert analyses and insights. Frank Corva writes about Bitcoin adoption around the world. Recursive Capital invests exclusively in early-stage companies based ...